Baidu
map

Cell:哇!单基因可逆转结肠癌 重建正常组织功能

2015-06-24 佚名 生物谷

近日,来自美国的科学家在国际学术期刊cell发表了一项最新研究进展,与以往直接杀死肿瘤细胞的策略不同,他们发现在小鼠中将一个与人类结肠癌有关的基因恢复到正常水平可以抑制肿瘤生长并在4天内重建正常的小肠功能。更令人惊奇的是,肿瘤在两周内慢慢消除,癌症症状也在随后的几个月内得到了改善。结肠癌是发达国家中导致癌症相关死亡的第二号杀手,每年全世界大约有700,000人死于结肠癌。目前治疗晚期结肠癌的主要策

近日,来自美国的科学家在国际学术期刊cell发表了一项最新研究进展,与以往直接杀死肿瘤细胞的策略不同,他们发现在小鼠中将一个与人类结肠癌有关的基因恢复到正常水平可以抑制肿瘤生长并在4天内重建正常的小肠功能。更令人惊奇的是,肿瘤在两周内慢慢消除,癌症症状也在随后的几个月内得到了改善。结肠癌是发达国家中导致癌症相关死亡的第二号杀手,每年全世界大约有700,000人死于结肠癌。目前治疗晚期结肠癌的主要策略还是不同化疗药物的联合治疗,这种方法毒性大并且治疗效率并不高,但在过去十年中,结肠癌的治疗仍以此方法为主。

 
研究人员指出,高达90%的结肠癌包含一种叫作adenomatous polyposis coli(Apc)的肿瘤抑制基因的失活突变,有研究证明这些基因突变在结肠癌起始过程中有重要作用,但Apc失活是否在肿瘤发生之后的肿瘤生长和存活过程中也扮演重要角色仍未可知。
 
在该项研究中,研究人员利用一种基因操作技术在一种结肠癌小鼠模型中精确并可逆地重新激活了Apc活性。在目前大多数结肠癌小鼠模型中,肿瘤主要发生在小肠,而该研究所使用的小鼠模型肿瘤不仅发生在小肠还会发生在结肠,与人类结肠癌的发生更加类似。在对Apc活性进行重新激活之后,wnt信号恢复到正常水平,肿瘤细胞也停止了增殖,同时小肠细胞也恢复了正常功能,随后两周内,肿瘤受到抑制并逐渐消失,研究人员又进行了6个月跟踪观察也没有发现癌症有复发迹象。除此之外,研究人员指出这种方法对于治疗携带Kras和p53突变的恶性结肠癌也非常有效。
 
综上所述,这项研究发现在结肠癌小鼠模型中重新激活Apc基因表达可以抑制肿瘤生长,恢复小肠正常功能。这为利用重建单个肿瘤抑制性基因抑制肿瘤生长的方法提供了重要证据,表明这一方法可成为癌症治疗的新策略。

原始出处:

Lukas E. Dow56, Kevin P. O’Rourke5, Janelle Simon, Darjus F. Tschaharganeh, Johan H. van Es, Hans Clevers, Scott W. Lowe.Apc Restoration Promotes Cellular Differentiation and Reestablishes Crypt Homeostasis in Colorectal Cancer.Cell, June 18, 2015.DOI: http://dx.doi.org/10.1016/j.cell.2015.05.033

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1959400, encodeId=6a5e1959400ed, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Oct 31 05:07:00 CST 2015, time=2015-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869146, encodeId=65d7186914611, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jul 16 05:07:00 CST 2015, time=2015-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30703, encodeId=662b30e032d, content=可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Sat Jul 04 23:03:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29122, encodeId=e3fb29122af, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:16:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28896, encodeId=fde528896bd, content=怎么实现呢?, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48ce1618316, createdName=stupidox, createdTime=Thu Jun 25 14:49:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28790, encodeId=84c728e9041, content=基因很强大, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Jun 25 06:45:00 CST 2015, time=2015-06-25, status=1, ipAttribution=)]
    2015-10-31 智智灵药
  2. [GetPortalCommentsPageByObjectIdResponse(id=1959400, encodeId=6a5e1959400ed, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Oct 31 05:07:00 CST 2015, time=2015-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869146, encodeId=65d7186914611, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jul 16 05:07:00 CST 2015, time=2015-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30703, encodeId=662b30e032d, content=可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Sat Jul 04 23:03:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29122, encodeId=e3fb29122af, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:16:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28896, encodeId=fde528896bd, content=怎么实现呢?, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48ce1618316, createdName=stupidox, createdTime=Thu Jun 25 14:49:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28790, encodeId=84c728e9041, content=基因很强大, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Jun 25 06:45:00 CST 2015, time=2015-06-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1959400, encodeId=6a5e1959400ed, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Oct 31 05:07:00 CST 2015, time=2015-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869146, encodeId=65d7186914611, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jul 16 05:07:00 CST 2015, time=2015-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30703, encodeId=662b30e032d, content=可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Sat Jul 04 23:03:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29122, encodeId=e3fb29122af, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:16:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28896, encodeId=fde528896bd, content=怎么实现呢?, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48ce1618316, createdName=stupidox, createdTime=Thu Jun 25 14:49:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28790, encodeId=84c728e9041, content=基因很强大, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Jun 25 06:45:00 CST 2015, time=2015-06-25, status=1, ipAttribution=)]
    2015-07-04 Gsurgeon

    可以

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1959400, encodeId=6a5e1959400ed, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Oct 31 05:07:00 CST 2015, time=2015-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869146, encodeId=65d7186914611, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jul 16 05:07:00 CST 2015, time=2015-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30703, encodeId=662b30e032d, content=可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Sat Jul 04 23:03:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29122, encodeId=e3fb29122af, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:16:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28896, encodeId=fde528896bd, content=怎么实现呢?, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48ce1618316, createdName=stupidox, createdTime=Thu Jun 25 14:49:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28790, encodeId=84c728e9041, content=基因很强大, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Jun 25 06:45:00 CST 2015, time=2015-06-25, status=1, ipAttribution=)]
    2015-06-25 huaxipanxing

    看看

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1959400, encodeId=6a5e1959400ed, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Oct 31 05:07:00 CST 2015, time=2015-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869146, encodeId=65d7186914611, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jul 16 05:07:00 CST 2015, time=2015-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30703, encodeId=662b30e032d, content=可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Sat Jul 04 23:03:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29122, encodeId=e3fb29122af, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:16:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28896, encodeId=fde528896bd, content=怎么实现呢?, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48ce1618316, createdName=stupidox, createdTime=Thu Jun 25 14:49:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28790, encodeId=84c728e9041, content=基因很强大, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Jun 25 06:45:00 CST 2015, time=2015-06-25, status=1, ipAttribution=)]
    2015-06-25 stupidox

    怎么实现呢?

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1959400, encodeId=6a5e1959400ed, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Oct 31 05:07:00 CST 2015, time=2015-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869146, encodeId=65d7186914611, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Jul 16 05:07:00 CST 2015, time=2015-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30703, encodeId=662b30e032d, content=可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a6a1604604, createdName=Gsurgeon, createdTime=Sat Jul 04 23:03:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29122, encodeId=e3fb29122af, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:16:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28896, encodeId=fde528896bd, content=怎么实现呢?, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48ce1618316, createdName=stupidox, createdTime=Thu Jun 25 14:49:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28790, encodeId=84c728e9041, content=基因很强大, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Jun 25 06:45:00 CST 2015, time=2015-06-25, status=1, ipAttribution=)]
    2015-06-25 nizongzan

    基因很强大

    0

相关资讯

STM:结肠癌药物治疗的新选择

来自新加坡南洋理工大学(NTU Singapore)和欧洲最大的医科大学——瑞典卡罗林斯卡医学院的研究人员发现,现有用于治疗白血病的化疗药物可以预防和控制结直肠肿瘤的生长。大肠癌是常见的恶性肿瘤,包括结肠癌和直肠癌。大肠癌的发病率从高到低依次为直肠、乙状结肠、盲肠、升结肠、降结肠及横结肠,近年有向近端(右半结肠)发展的趋势。其发病与生活方式、遗传、大肠腺瘤等关系密切。发病年龄趋老年化,男女之比为1

Lancet:卡培他滨联合贝伐单抗治疗转移性结肠癌效果良好

目前,在临床上针对转移性结肠癌的一线治疗方式:化疗联合北伐单抗疗法的最优治疗时间仍然是未知的。CAIRO3试验的研究目的在于评估卡培他滨联合贝伐单抗进行维持治疗与观察组相比疗效何如。该结果在线发表于2015年4月8日的The Lancet杂志上。 该研究是一项开放、随机对照的3期临床试验。研究人员从荷兰国内64个医院招募受试患者。纳入标准为年龄大于18岁,患转移性结肠癌,未曾接受过治疗,在6个3

Ann Oncol:早期结肠癌生存期与普通人群(MGP)生存期比较

在文献中关于早期结肠癌(CC)患者后生存治疗描述得很详细,对患者来说治愈是可能的。然而,在经治疗患者的生存期与相匹配普通人群(MGP)比较的研究是有限的。 研究人员收纳了在1977-2012年间在41个国家实施的25个随机辅助试验中的32745名患者。观察所收纳患者长期生存期,与性别,年龄,国家,和时间相匹配的预期生存期,总生存和疾病分期(II期和III期),性别,治疗[手术,5-氟尿嘧啶(5-

Cell Stem Cell:促进结肠癌生长的重要癌症干细胞群体

最近,来自劳森健康研究所的研究人员在结肠中发现一个新的干细胞群与结肠癌生长具有重要联系。近日,相关研究结果发表在国际学术期刊Cell Stem Cell。 结肠癌是加拿大癌症相关死亡的第二号杀手,据估计2015年将有25,100名加拿大人患上结肠癌,占所有新发癌症病例的13%。 在该项研究中,研究人员在结肠癌中发现了一群新的癌症干细胞,这群细胞具有寿命长以及放射性抵抗的特性。更

JAMA Surg:年轻结肠癌患者的过度治疗

50年间,结肠癌的发病率年轻群体不断增加。然而,年轻结肠癌患者的预后仍然与人口、疾病和治不同治疗方式之间是否有显著的关联,尚未有明确的结论。 本研究对年轻的成年人(49岁以下)与老年人(年龄在65 - 75岁间)比较来研究在临床试验环境外而在现实生活中存在的年龄相关变量,如患者、肿瘤、治疗等因素对特定分级的肿瘤治疗和预后的结果差距。。 这项队列研究数据来自美国国家癌症数据库并收纳了来自2003

Baidu
map
Baidu
map
Baidu
map